What insurance policy changes affect code D81.818?

There are 2 tracked policy changes affecting code D81.818, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code D81.818?

Payers that have issued tracked updates for code D81.818 include: Aetna.

How do I get notified when code D81.818 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code D81.818. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code D81.818?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

D81.818 Insurance Policy Changes

ICD-10 D81.818 is officially defined as "Other biotin-dependent carboxylase deficiency." code D81.818 is referenced in 2 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code D81.818 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Only a small number of policies match this filter. Check back as coverage expands.

Aetna · Identified Aug 19, 2026Medium impact
Homocysteine Testing (CPB 0763, reviewed 2025-11-12)
Aetna covers homocysteine testing (CPT 83090) for borderline vitamin B12 deficiency when the results will affect management, for central retinal vein occlusion in members with a history or family history of thrombosis or who are under 56 years of age without strong arteriosclerotic risk factors, for homocystinuria caused by cystathionine beta-synthase deficiency, and for idiopathic or recurrent venous thromboembolism, thrombosis under 45 years of age, or thrombosis at an unusual site. Testing for all other listed indications, including management of 5,10-methylenetetrahydrofolate reductase (MTHFR) abnormalities, cardiovascular or stroke risk assessment, dementia and depression, is considered experimental, investigational or unproven because its effectiveness for these indications has not been established. Covered ICD-10 codes include D51.0 through D51.9, D81.818, D81.819, E53.8, I81 and I82.0 through I82.91.
Aetna · Identified Oct 30, 2026Low impact
Homocysteine Testing (CPB 0763, reviewed 2026-10-28)
Aetna clinical policy bulletin CPB 0763 covers homocysteine testing and was last reviewed 10/28/2026. It lists the indications Aetna considers medically necessary, including CPT 83090 and the covered ICD-10 codes listed in the bulletin, and it states that Aetna considers homocysteine testing experimental, investigational, or unproven for all other indications. The source text does not describe what changed in this review.

Watch D81.818

Get one email when a payer policy names D81.818, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Homocysteine Testing (CPB 0763, reviewed 2025-11-12)

Homocysteine Testing (CPB 0763, reviewed 2026-10-28)

What insurance policy changes affect code D81.818?

Which payers have updated policy for code D81.818?

How do I get notified when code D81.818 policy changes?

Why do payers change policies for code D81.818?